Evidence map›Paper›PMID 39664232›Full record

ArticleTherapeutic advances in gastroenterology2024

Infliximab monitoring in Crohn's disease: a neural network approach for evaluating disease activity and immunogenicity.

Luis Eduardo Miani Gomes, Livia Moreira Genaro, Marina Moreira de Castro, Renato Lazarin Ricci, Livia Bitencourt Pascoal, Filipe Botto Crispim Silva, Pedro Henrique Leite Bonfitto, Michel Gardere Camargo, Ligiana Pires Corona, Maria de Lourdes Setsuko Ayrizono and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Luis Eduardo Miani GomesInflammatory Bowel Disease Research Laboratory (LabDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Livia Moreira GenaroInflammatory Bowel Disease Research Laboratory (LabDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Marina Moreira de CastroInflammatory Bowel Disease Research Laboratory (LabDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Renato Lazarin RicciInflammatory Bowel Disease Research Laboratory (LabDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Livia Bitencourt PascoalInflammatory Bowel Disease Research Laboratory (LabDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Filipe Botto Crispim SilvaInflammatory Bowel Disease Research Laboratory (LabDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Pedro Henrique Leite BonfittoInflammatory Bowel Disease Research Laboratory (LabDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Michel Gardere CamargoInflammatory Bowel Disease Research Laboratory (LabDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Ligiana Pires CoronaNutritional Epidemiology Laboratory, School of Applied Sciences, University of Campinas, Limeira, São Paulo, Brazil.
Maria de Lourdes Setsuko AyrizonoInflammatory Bowel Disease Research Laboratory (LabDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Anibal Tavares de AzevedoSimulation Laboratory, School of Applied Sciences, University of Campinas, Limeira, São Paulo, Brazil.
Raquel Franco LealInflammatory Bowel Disease Research Laboratory (LabDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Carlos Chagas Street, 420, Cidade Universitária Zeferino Vaz, Campinas 13083-878, São Paulo, Brazil.ORCID https://orcid.org/0000-0003-4285-4402

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The treatment for Crohn's disease (CD) has increasingly required the use of biological agents. Safe and affordable tests have led to the active implementation of therapeutic drug monitoring (TDM) in clinical practice, which, although not yet widely available across all health services, has been proven effective. Objective: To analyze serum infliximab (IFX) and antidrug antibody (ADA) levels in CD patients, compare two tests, as well as construct a prediction of neural network using a combination of clinical, epidemiological, and laboratory variables. Design: Cross-sectional observational study. Method: A cross-sectional observational study was conducted on 75 CD patients in the maintenance phase of IFX treatment. The participants were allocated into two groups: CD in activity (CDA) and in remission (CDR). Disease activity was defined by endoscopic or radiological criteria. Serum IFX levels were measured by enzyme-linked immunosorbent assay (ELISA) and rapid lateral flow assay; ADA levels were measured by ELISA. A nonparametric test was used for statistical analysis; Results: Most participants exhibited supratherapeutic IFX levels (>7 mg/mL). Both tests showed no difference in IFX levels between the CDA and CDR groups ( Conclusion: Most participants exhibited supratherapeutic IFX levels, with no significant serum level difference between the groups. There was moderate agreement between tests. Two neural network sets showed disease activity and the presence of ADA, noninvasively determined in patients using IFX by presenting an AUC of >80%.

Indexed as

antidrug antibodyCrohn’s diseasedrug monitoringinfliximabneural network

Identifiers

PMID39664232
PMCPMC11632880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.